Latest news with #Enki™
Yahoo
11-07-2025
- Business
- Yahoo
Rakovina Therapeutics Congratulates Partner - Variational AI for Winning LifeSciencesBC's 2025 Emerging Biotech Company of the Year Award
Award Recognition underscores the importance of AI-driven drug discovery VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ('Rakovina' or the 'Company') (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through AI-powered drug discovery proudly congratulates partner, Variational AI, on being honored as the 2025 Emerging Company of the Year – Biotech by Life Sciences BC. This prestigious award recognizes a British Columbia-based biotechnology company demonstrating exceptional progress and achievement of key strategic milestones, attributes that reflect Variational AI's impressive momentum and innovation in the field. Since entering into a partnership with Rakovina Therapeutics in September 2024, Variational AI has applied its Enki™ generative AI platform to accelerate the discovery of novel DNA damage response (DDR) kinase inhibitors. Most recently, the platform has been used to advance the KT-5000 series, the newest generation of synthetic small-molecule candidates targeting DDR pathways. This collaboration has produced multiple structurally novel compounds with favorable drug-like properties and activity in validated cancer cell lines. Early data suggest these candidates hold strong promise as brain-penetrant agents for difficult-to-treat tumors and represent a significant step forward in the Company's AI-powered discovery pipeline.'We're proud to see Variational AI recognized as Emerging Biotech Company of the Year,' said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. 'This award highlights the transformative role of AI in drug discovery and reinforces the strength of our collaboration. Variational's Enki™ platform has helped us identify novel drug candidates with remarkable speed and precision, and we look forward to advancing these promising therapies together.'About Variational AI Variational AI has developed Enki™, the first commercially available foundation model for small-molecule drug discovery. By leveraging generative AI, Variational AI enables biopharmaceutical companies to rapidly discover and optimize novel, potent, safe, and synthesizable lead compounds at a fraction of the time and cost of traditional approaches. For more information, visit About Rakovina Therapeutics Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ platform. By using AI, we can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice Regarding Rakovina Therapeutics Forward-Looking Statements: This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans,' 'is expected,' 'expects,' 'scheduled,' 'intends,' 'contemplates,' 'anticipates,' 'believes,' 'proposes' or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results 'may,' 'could,' 'would,' 'might,' or 'will' be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company's most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company's profile page at For Further Information Contact:Michelle Seltenrich, BSc MBADirector, Corporate DevelopmentIR@
Yahoo
22-04-2025
- Business
- Yahoo
Rakovina Therapeutics Congratulates Scientific Advisor Dr. Artem Cherkasov on Global Recognition for Breakthrough AI Innovation in Drug Discovery
VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to congratulate its Scientific Advisor and collaborator, Dr. Artem Cherkasov, on his recent global recognition as a leader in AI-driven therapeutic development. Dr. Cherkasov, a professor at the University of British Columbia and a principal investigator with the Vancouver Prostate Centre, was recently featured by the Vancouver Coastal Health Research Institute (VCHRI) in an article titled 'AI innovation puts VCHRI scientist at forefront of global drug discovery avenues.' The feature highlights his groundbreaking contributions to the use of artificial intelligence in computational drug modeling and the development of the Deep Docking™ platform—an AI engine capable of screening billions of molecules to identify the most promising drug candidates with speed and precision. As a key scientific advisor to Rakovina Therapeutics, Dr. Cherkasov plays an integral role in guiding the company's AI-driven discovery efforts. Rakovina holds exclusive access to the Deep Docking™ platform for the development of novel DNA-damage response (DDR) inhibitors—an approach designed to accelerate therapeutic discovery and improve treatment outcomes for cancers with limited options. 'Dr. Cherkasov's global recognition is a well-earned reflection of his pioneering spirit and the transformative power of AI in oncology drug development,' said Jeffrey Bacha, executive chairman of Rakovina Therapeutics. 'Our collaboration with Dr. Cherkasov allows us to integrate cutting-edge AI into our discovery engine, positioning Rakovina at the forefront of innovation in targeted cancer therapy.' Rakovina Therapeutics remains committed to leveraging world-class science and technology to develop new treatments for patients with difficult-to-treat cancers. The company is proud to partner with Dr. Cherkasov in this mission. About Rakovina Therapeutics Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ and Enki™ platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice Regarding Rakovina Therapeutics Forward-Looking Statements: This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans,' 'is expected,' 'expects,' 'scheduled,' 'intends,' 'contemplates,' 'anticipates,' 'believes,' 'proposes' or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results 'may,' 'could,' 'would,' 'might,' or 'will' be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company's most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company's profile page at For Further Information Contact:Michelle Seltenrich, BSc MBADirector, Corporate DevelopmentIR@
Yahoo
06-02-2025
- Business
- Yahoo
Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program
VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response technologies, announces continued advancement of its AI-driven drug discovery program. Over the next four months, additional small-molecule drug candidates, designed in collaboration with Pharma Inventor Inc., will be synthesized and delivered for further evaluation. The expanded program builds on the success of the first batch of AI-designed PARP1-selective inhibitors announced earlier this year. These new compounds are being tailored to optimize efficacy, safety, and pharmacokinetic profiles, targeting critical unmet needs in oncology, including central nervous system (CNS) malignancies. Separately, Rakovina Therapeutics expects to receive the first synthesized drug candidates from its second AI-driven drug discovery program targeting ATR. AI-derived drug candidates are first validated in silico before being synthesized and evaluated for in vitro and in vivo activity against a specific target product profile in the Company's laboratories at the University of British Columbia. Rakovina Therapeutics plans to advance the most promising lead candidates into human clinical trials in collaboration with pharmaceutical industry partners. Leveraging AI for Revolutionary Advances in Cancer Treatment The potential of artificial intelligence to accelerate medical breakthroughs has never been more apparent. Recent comments from leaders in AI and healthcare highlight the transformative role this technology will play in curing diseases at an unprecedented pace. Sam Altman, CEO of OpenAI, recently stated, 'We will see diseases get cured at an unprecedented rate. We will be amazed at how quickly we're curing this cancer and that one — and heart disease. AI will cure the diseases at a rapid, rapid rate.' Similarly, Oracle CEO Larry Ellison emphasized AI's ability to revolutionize early cancer detection and personalized treatments, stating, 'If you can do it using AI, you can do early cancer detection with a blood test... Once we gene sequence that cancer tumor, you can then vaccinate the person — design a vaccine for every individual person... in about 48 hours.' These bold predictions align with Rakovina's approach to combine cutting-edge AI with world-class scientific expertise. By leveraging AI platforms like Deep Docking™ and Enki™, Rakovina Therapeutics is poised to contribute to this new era of rapid medical advancements, accelerating the development of innovative cancer therapies. Advancing Innovation and Expanding Potential Each set of compounds is being developed to address specific therapeutic gaps, including the treatment of cancers that involve the brain, such as BRCA-mutated metastatic breast cancer and glioblastoma. Leveraging its collaborations for utilizing the Deep Docking and Enki systems, Rakovina continues to employ cutting-edge artificial intelligence to accelerate drug discovery and bring meaningful therapies closer to patients in need. 'This expansion demonstrates the scalability and impact of our AI platform partnership,' said Prof. Mads Daugaard, Chief Scientific Officer. 'With additional compounds in the pipeline, we are dramatically increasing the potential for identifying novel therapeutics to tackle some of the most challenging cancers. This ongoing development exemplifies our commitment to innovation and efficiency in cancer research.' Jeffrey Bacha, Executive Chairman, added, 'The addition of these AI-designed compounds significantly broadens our pipeline potential and will accelerate progress toward delivering life-changing treatments. By rapidly scaling our efforts, we are addressing the growing demand for innovative cancer therapies with unprecedented precision and speed.' About Rakovina Therapeutics Inc. Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ platform. By using AI, we can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice Regarding Rakovina Therapeutics Forward-Looking Statements: This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans,' 'is expected,' 'expects,' 'scheduled,' 'intends,' 'contemplates,' 'anticipates,' 'believes,' 'proposes' or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results 'may,' 'could,' 'would,' 'might,' or 'will' be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company's most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company's profile page at For Further Information Contact:Michelle Seltenrich, BSc MBADirector, Corporate DevelopmentIR@
